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Antimitochondrial antibodies (AMAs) are the classic serologic marker in primary biliary cirrhosis
(PBC). However, there have been only limited attempts to study changes in titer or isotype analysis of
such AMAs in patients followed for long periods of time.
We took advantage of stored sera from well-characterized patients with PBC followed for a period of
7–28 years (mean duration of 13.5 years). Immunoblot and enzyme-linked immunosorbant assays were
performed against PDC-E2, BCOADC-E2 and OGDC-E2 as well as isotype analysis of antigen-speciﬁc
IgG, IgA and IgM antibodies against each of these mitochondrial autoantigens. Sera were analyzed for
total IgG, IgA and IgM by radial immunodiffusion. The sera titer of AMAs was signiﬁcantly higher in
younger patients with PBC. Indeed, age of onset of clinical PBC was a signiﬁcant predictor for the
highest values of sera AMAs. In contrast, the AMA titer did not signiﬁcantly change over time in this
prolonged longitudinal study. The total sera levels of the individual immunoglobulins did not show a
time-dependent change, when based on age of onset of the disease. Higher titers of AMAs were noted in
the younger patients. Furthermore, despite this long follow-up, there was no evidence for a signiﬁcant
change in AMA levels; also, levels were not inﬂuenced by drug therapy used during the period of
observation.
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INTRODUCTION
The presence of antimitochondrial antibodies (AMAs)
have been known to be associated with primary biliary
cirrhosis (PBC) for more than four decades (Mackay,
1958; Walker et al., 1965). The rigorous deﬁnition of the
antigens recognized by anti-mitochondrial antibodies have
helped in our understanding of not only the speciﬁcity of
these autoantibodies, but also the association of T cell
reactivity with the same antigens (Gershwin et al.,1 9 8 7 ;
Shimoda et al., 1998; Gershwin et al., 2000; Kita et al.,
2002a,b). AMAs have become important in the evaluation
of patients with chronic liver disease and have provided
the impetus for the early diagnosis of PBC (James et al.,
1981; Metcalf et al., 1996). There have been a variety of
immunological procedures used for their identiﬁcation,
most commonly indirect immunoﬂuorescence (IF),
immunoblot assays and enzyme-linked immunosorbant
assays (ELISA) (Leung et al., 1997). These assays are of
varying sensitivity, speciﬁcity and complexity.
The major autoantigens recognized by sera from
patients with PBC have been identiﬁed as members of
the 2-oxo-acid dehydrogenase complex (2-OADC),
including the E2 subunit of the pyruvate dehydrogenase
complex (PDC-E2), the E2 subunit of the branched chain
2-oxo-acid dehydrogenase complex (BCOADC-E2) and
the E2 subunit of the 2-oxo glutarate dehyrogenase
complex (OGDC-E2) (Gershwin et al., 1987; Leung and
Gershwin, 1989). Dihydrolipoamide dihydrogenase or
PDC-E2 is the major autoantigen of PBC and is
recognized by 80–90% of sera (Van de Water et al.,
1988). In about 60% of PBC patients there is reactivity
with BCOADC-E2; some 4–13% will recognize only
BCOADC-E2. OGDC-2E is recognized by 30–80% of
sera and, rarely, may be the only reaction in established
PBC (Miyakawa et al., 2001). Availability of these
individual recombinant autoantigens and a triple
expression hybrid clone has facilitated development of a
highly speciﬁc and sensitive ELISA. In a comparison
study of 191 patients, 161 or 84% were AMA-positive by
IF and 179 or 94% by ELISA using recombinant antigens.
Twenty-two (73%) of the 30 patients that were AMA-
negative by IF were AMA-positive with this ELISA assay;
all controls were negative and there were no false
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2001). We chose this latter technology and applied it to a
collection of stored sera from PBC patients followed up
for a period of 7–28 years. This allowed us to quantitate
AMAs over an extended period. In addition, the levels of
sera immunoglobulins were compared at the beginning
and end of the period of observation.
MATERIALS AND METHODS
Patients
Twenty patients with PBC diagnosed with the character-
istic clinical and pathological features (Sherlock and
Scheuer, 1973; Kaplan, 1987; Neuberger, 1997) were
followed for 7–28 years for a mean of 13.5 years.
Nineteen were women; age ranged from 25 to 73 years at
the time of initial evaluation. During the period of
observation, 5 were treated with ursodeoxycholate, 6 with
colchicine and 7 with a combination of the two agents.
There were no instances of liver failure and none required
liver transplantation.
Sera Immunoglobulins
Immunoglobulins levels were determined by radial
immunodiffusion; normal ranges were IgG (820–
1740mg/dl), IgA (90–400mg/dl) and IgM (52–
270mg/dl).
Antimitochondrial Antibodies
Immunoblot assays were performed on sera at a dilution of
1:100 utilizing a bovine heart mitochondrial preparation
(Miyakawa et al., 1999). Sera were assayed for PDC-E2,
BCOADC-E2 and OGDC-E2 utilizing a polyvalent
secondary antibody to human Ig and individual antibodies
for IgG, IgA and IgM, including monospeciﬁc antibodies
for IgG class and isotypes, IgG1-4. The unique
Escherichia coli buffer was used and the cut-off for
determining positivity was the mean of the controls þ 10
SD. These methods have been previously described
(Miyakawa et al., 2001). Similarly, the sera were assayed
using the triple expression hybrid clone, MIT3, with a
polyvalent secondary antibody to Ig and individual
antibodies for IgG, IgA and IgM (Moteki et al., 1996;
Miyakawa et al., 2001). In all cases, recombinant
autoantigens were used and quality controls, including
duplicate assays, were performed; results were appro-
priately diluted to insure linearity. In addition, the
inﬂuence of therapy was determined. For analysis of
data, a multivariate analysis of variance model (MAN-
OVA) was used, including the outcome variable for
immunoglobulin levels and the ELISA values against
individual autoantigens and their isotypes. For many of
the variables, a transformation was required to satisfy the
assumption of normality for the comparisons of the
means of the ﬁrst and last samples from each subject.
In presenting the “means” and conﬁdence intervals
in the tables, we “back-transformed” those variables to
the original scale when a transformation was necessary.
The back-transformation prevents us from giving standard
errors of the estimates (as well as from interpreting
the back-transformed mean as an arithmetic mean).
Rather, it is preferable to obtain a conﬁdence interval and
back-transform it to give a conﬁdence interval for the
population center (interpreted literally, this would be
the population median) (Bland and Altman, 1996).
RESULTS
Eighty samples from these 20 well-characterized patients
were tested; one subject was eliminated from the
comparison analysis because AMA was considered to be
absent at the time of the initial evaluation and continued to
be absent during the period of observation. Serum from
this patient indicated presence of PDC-E2 with the
immunoblot assay but the level failed to exceed the cut-off
established for the ELISA. All values for the sera collected
at time of diagnosis will be compared to the last sample
available from each patient. Table I shows the immuno-
globulin levels for IgG, IgA and IgM. The total serum IgG
and IgA levels did not change during this extended period
of observation. There was a decrease in the mean IgM
levels from 368 to 267mg/dl and a decrease in abnormal
levels from 13/19 (68%) to 9/19 (47%) but the changes
were not signiﬁcant. Results of the immunoblot assays are
shown in Table II. In sera collected at the time of
diagnosis, 18/19 (95%) showed a reaction with PDC-E2,
15/19 (79%) with BCOADC-E2 and 12/19 (63%) with
OGDC-E2. Serum from a single patient (5%) reacted only
with BCOADC-E2. There were no signiﬁcant changes
between sera collected at the beginning and end of
observation. Table III shows the results of the quantitative
ELISA for analysis of the three major autoantigens,
TABLE I Levels of sera immunoglobulins
First observation Last observation
Ig levels (mg/dl) Mean 95% CI Abnormals Mean 95% CI Abnormals p-Value
IgG 1442 (1218, 1666) 3 1454 (1176, 1733) 4 0.893
IgA 203 (159, 247) 1 232 (172, 291) 2 0.162
IgM 368 (277, 459) 13 267 (206, 328) 9 0.071
N ¼ 19; mean duration of 13.5 years. The total IgG and IgA levels did not change. There was a decrease in IgM levels but the decrease was not signiﬁcant, although the
number of values that exceeded the normal range decreased from 13 to 9.
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speciﬁc antibodies for class and isotypes. The values were
remarkably stable during this extended period of
observation but there were a few signiﬁcant changes,
e.g. the anti-IgA antibody to the autoantigen, PDC-E2
showed an increase, whereas the anti-IgG and anti-IgM
antibodies to BCOADC-E2 showed a decrease. Further
analysis showed that the sera titer of AMAs was
signiﬁcantly higher in younger patients with PBC
(p-value ¼ 0.0002). Indeed, age of onset of PBC posed
a signiﬁcant predictor for the highest values of sera
AMAs. Therapy with ursodeoxycholate ðp ¼ 0:687Þ;
colchicine ðp ¼ 0:473Þ or the combination ðp ¼ 0:583Þ
had no effect on the levels. Results of the assays for the
AMAs recognizing the recombinant the triple-expression
hybrid clone autoantigens, MIT3, are given in Table IV.
A polyvalent second antibody to human Ig as well as
individual antibodies, anti-IgG, IgA and IgM, were
utilized. No signiﬁcant changes in antibody levels were
noted during this period of observation.
DISCUSSION
Although previous surveys have identiﬁed AMA several
years before recognition of abnormal liver studies or
TABLE III Quantitative ELISA for the major autoantigens, PDC-E2, BCOADC-E2 and OGDC-E2
First observation Last observation
mean 95% CI mean 95% CI p-Value
PDC-E2 ELISA
IgG 0.728 (0.422, 1.035) 0.779 (0.489, 1.069) 0.531
Isotypes:
G1 0.030 (0.025, 0.038) 0.029 (0.026, 0.033) 0.706
G2 0.180 (0.101, 0.319) 0.221 (0.117, 0.418) 0.416
G3 0.631 (0.277, 0.984) 0.780 (0.317, 1.243) 0.443
G4 0.109 (0.078, 0.139) 0.112 (0.080, 0.143) 0.885
IgA 0.043 (0.026, 0.071) 0.061 (0.038, 0.100) 0.013
IgM 0.183 (0.113, 0.295) 0.188 (0.115, 0.306) 0.897
BCOADC-E2 ELISA
IgG 0.117 (0.044, 0.310) 0.082 (0.032, 0.212) 0.022
Isotypes:
G1 0.059 (0.054, 0.065) 0.052 (0.048, 0.058) 0.077
G2 0.127 (0.092, 0.203) 0.109 (0.081, 0.165) 0.169
G3 0.095 (0.060, 0.151) 0.099 (0.051, 0.191) 0.875
G4 0.103 (0.076, 0.139) 0.100 (0.075, 0.134) 0.755
IgA 0.022 (0.018, 0.028) 0.024 (0.018, 0.032) 0.389
IgM 0.138 (0.076, 0.248) 0.073 (0.033, 0.159) 0.047
OGDC-E2 ELISA
IgG 0.051 (0.023, 0.115) 0.050 (0.024, 0.106) 0.849
Isotypes:
G1 0.055 (0.046, 0.066) 0.053 (0.047, 0.060) 0.775
G2 0.089 (0.074, 0.110) 0.092 (0.076, 0.118) 0.589
G3 0.039 (0.027, 0.055) 0.045 (0.029, 0.069) 0.422
G4 0.057 (0.048, 0.067) 0.053 (0.045, 0.063) 0.528
IgA 0.068 (0.017, 0.119) 0.052 (0.027, 0.077) 0.324
IgM 0.047 (0.025, 0.091) 0.400 (0.020, 0.080) 0.327
The values were remarkably stable during this extended period of observation but there were a few signiﬁcant changes, e.g. the anti-IgA antibody to the autoantigen, PDC-E2
showed an increase, whereas the anti-IgG and anti-IgM antibodies to BCOADC-E2 showed a decrease.
TABLE II Immunoblotting to recombinant mitochondrial proteins
First observation
(N=19)
Last observation
(N=19)
PDC-E2
IgG class 17 18
IgA class 16 17
IgM class 18 17
At least 1 of them 18 18
BCOADC-E2
IgG class 14 15
IgA class 8 6
IgM class 15 13
At least 1 of them 15 16
OGDC-E2
IgG class 11 10
IgA class 0 0
IgM class 11 6
At least 1 of them 12 11
PDC-E2 þ BCOADC-E2
þ OGDC-E2
81 0
PDC-E2 þ BCOADC-E2 5 5
PDC-E2 þ OGDC-E2 4 1
PDC-E2 alone 1 2
BCOADC-E2 alone 1 1
OGDC-E2 alone 0 0
N ¼ 19; mean duration of 13.5 years. In sera collected at the time of diagnosis,
18/19 (95%) showed a reaction with PDC-E2, 15/19 (79%) with BCOADC-E2 and
12/19 (63%) with OGDC-E2. Serum from a single patient (5%) reacted only with
BCOADC-E2. There were no signiﬁcant changes between sera collected at the
beginning and end of observation.
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et al., 1981), there is scant information concerning
autoantibody levels during the clinical course of the
disease. The fact that 95% of patients with PBC are now
recognized to have AMA with current methodology,
suggests that the majority have had the antibody for years
before laboratory or clinical features are recognized.
Indeed, it seems unlikely that the patient with PBC who is
truly negative, is likely to become positive once the
clinical diagnosis is established on laboratory or
histological changes. The persistence of stable antibody
levels during the course of the illness, suggests that there
is either a continued immunological insult that perpetuates
production of AMA or, alternatively, the AMA at the time
of disease recognition is already a long-established
antibody activity following a potent antigenic stimulus.
These results suggest that the AMA response was
established long before the clinical diagnosis of PBC.
In fact, random surveys of large numbers of healthy
subjects have disclosed the presence of AMAs for several
years before clinical diagnosis (Mattalia et al., 1998;
Gershwin et al., 2000). Thus, it is not surprising that the
AMA titer does not change over time to a signiﬁcant
extent. An analogy can be made to anti-tetanus and
diphtheria responses, both of whom will continue with
high titer for several decades following the last
immunization. In fact, this data is also consistent with
the relatively small change which occurs in AMA titer
following liver transplantation (Van de Water et al., 1996;
Luettig et al., 1998).
This study was valuable because of the characteristics
of the sera from the same patients followed for this unique
period of time.Although these patients may not be entirely
representativeof the spectrum of disease observedin PBC,
they do provide an important framework and the data
should be discussed with relation to similar observations.
For example, changes in immunoglobulin levels have long
been noted in association with chronic liver disease
(Eliakim et al., 1972). In PBC, IgM has been found to be
increased (Paronetto et al., 1964; Bevan, 1966; Feizi,
1968; Walker and Doniach, 1968), an increase which may
be supportive of the diagnosis when AMA is absent or
present in low titer (Bevan et al., 1969). Immunoglobulin
M was elevated in 13/19 (68%) at the time of diagnosis in
this group. Although the abnormal levels decreased to
9/19 (47%) during observation, the decrease was not
statistically signiﬁcant.
Reactivity to the three recombinant mitochondrial
proteins (Table II) are similar to other studies, in that
sera recognized 18/19 (95%) of PDC-E2, 15/19 (79%)
of BCOADC-E2 and 12/19 (63%) of OGDC-E2
(Miyakawa et al., 2001). A single serum recognized
only BCOADC-E2. The patterns of reactivity were
remarkably durable and there were only insigniﬁcant
changes. The results of a detailed analysis utilizing the
three major autoantigens, PDC-E2, BCOADC-E2 and
OGDC-E2 and the second antibodies, IgG, IgA and IgM,
plus IgG isotypes, G1-4, are given in Table III. Again, the
autoantibodies levels were remarkably stable. The only
signiﬁcant changes included an increase in IgA reactivity
to PDC-E2 and a decrease in IgG and IgM reactivity
to BCOADC-E2. Interestingly, the levels of AMA
were signiﬁcantly higher in younger patients at
the time of diagnosis. Indeed, age of onset of PBC was
a predictor for the highest AMA levels. There were no
signiﬁcant changes in the AMA levels when the MIT3
triple-expression hybrid autoantigen was used. The
epitope recognized by antimitochondrial antibodies is
similar to the region recognized by autoreactive CD4
þ and
CD8 T cells. More importantly, the T cell precursor
frequency in liver against these autoepitopes is up to 100
fold higher than it is in blood, suggesting that the
antimitochondrial response is either directly related to
disease pathogenesis, or else intimately related to disease
initiation (Shimoda et al., 1998; Kita et al., 2002a,b). We
suggest that future studies focus on the most recently
diagnosed patients with PBC and/or perhaps be able to
screen and identify sera from asymptomatic patients in
hopes of identifying the initiating event.
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